Also found in: Dictionary.
Related to Cardium: Cardium edule
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for Cardium

type genus of the family Cardiidae: cockles

References in periodicals archive ?
According to the company, these purchased assets would complement Pengrowth's existence in the Alberta Lochend Cardium light oil resource sector, increasing its Lochend Cardium land holdings to 44 net sections.
Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and InnerCool Therapies.
In January 2014, Cardium reported encouraging initial clinical pilot study findings from its ASPIRE international Phase 3 registration clinical study, which is designed to confirm the continued safety and effectiveness from four previously completed clinical studies of Generx as an interventional cardiology angiogenic gene therapy for the potential treatment of cardiac microvascular insufficiency, a condition that leads to myocardial ischemia due to advanced coronary artery disease http://www.
Dan Cave, president and CEO of Cardium Health + AirLogix, has led the integration of the two companies and provided the vision for the combined organization going forward.
Cardium has three business units: (1) Angionetic Therapeutics(TM), focused on the late-stage clinical development of Generx[sup.
Andrew's financial expertise, global business contacts, and industry insights will be beneficial to Cardium as we continue to execute on our business plans.
BlueMetric(TM), Decision Rule Adaption(TM), ADAPT(TM), Angionetics Biologics(TM), Activation Therapeutics(TM) are trademarks of Cardium Therapeutics, Inc.
is a newly-formed medical data analytics business that has been internally developed by researchers at Cardium.
SAN DIEGO -- Cardium Therapeutics (AMEX:CXM) today reported recent highlights and developments, as well as financial results for its second quarter ended June 30, 2007.
SAN DIEGO, July 19, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced the completion of the second tranche of its previously described registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.
SAN DIEGO, July 18, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) announced a 1-for-20 reverse split of the Company's issued and outstanding common stock effective at the open of the NYSE MKT Exchange today, July 18, 2013.
The registration statement registers the resale of Cardium common stock by the selling stockholders named in the registration statement of shares acquired by them in connection with a private placement of Cardium common stock and a reverse merger transaction, each of which was completed in October 2005.
SAN DIEGO, June 21, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) held its reconvened Annual Meeting of Stockholders earlier today and has temporarily adjourned the meeting to Tuesday, July 2, 2013, at 1:00 p.
SAN DIEGO -- Cardium Therapeutics (OTCBB:CDTP) announced the start of patient recruitment for its Phase 3 clinical trial (AWARE) to evaluate the therapeutic effects of Cardium's lead product candidate, Generx[TM] (alferminogene tadenovec, Ad5FGF-4), in women for the potential treatment of myocardial ischemia.